Reported Q: Q4 2025 Rev YoY: +93.3% EPS YoY: +186.0% Move: -0.89%
Safilo Group SpA
0NJ5.L
€1.673 -0.89%
Exchange LSE Sector Healthcare Industry Medical Instruments Supplies
Q4 2025
Published: Dec 31, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for 0NJ5.L

Reported

Report Date

Dec 31, 2025

Quarter Q4 2025

Revenue

445.75M

YoY: +93.3%

EPS

0.02

YoY: +186.0%

Market Move

-0.89%

Previous quarter: Q2 2025

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • Revenue of $445.75M up 93.3% year-over-year
  • EPS of $0.02 increased by 186% from previous year
  • Gross margin of 60.8%
  • Net income of 7.36M
  • "" -
0NJ5.L
Company 0NJ5.L

Swipe to view all report sections

Executive Summary

Safilo Group SpA reported Q4 2025 revenue of €445.8 million, down modestly year-over-year and down about 17% quarter-over-quarter, reflecting a seasonally weaker Q4 and ongoing demand normalization across key markets. Gross profit totaled €271.1 million with a solid gross margin of 60.8%, underscoring the durability of Safilo’s branded and licensed product mix despite top-line softness. Operating income remained negative at €1.2 million for the quarter, with EBITDA at a similar negative level, signaling ongoing cost absorption and the impact of softer volumes on operating leverage. Net income was €7.4 million for the quarter, delivering a positive bottom line despite the near-term profitability headwinds, supported by other income and cost controls.

Key Performance Indicators

Revenue
Increasing
445.75M
QoQ: -17.09% | YoY: 93.28%
Gross Profit
Increasing
271.05M
60.81% margin
QoQ: -17.42% | YoY: 98.14%
Operating Income
Decreasing
-1.21M
QoQ: -102.37% | YoY: -127.54%
Net Income
Increasing
7.36M
QoQ: -82.35% | YoY: 213.94%
EPS
Increasing
0.02
QoQ: -83.80% | YoY: 185.96%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q4 2025 445.75 0.02 +93.3% View
Q2 2025 268.81 0.05 +133.1% View
Q1 2025 268.81 0.05 +1.1% View
Q4 2024 461.26 0.01 -2.8% View
Q3 2024 230.63 0.01 -2.8% View